Bioject and Immunomic Therapeutics Enter Into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines

Share Article

Immunomic Therapeutics, Inc., (ITI), and Bioject have entered into an agreement for ITI to use Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ vaccine platform. This collaboration has the potential to further support acceleration of LAMP-vax product development.

“The right delivery is key to a well-designed vaccine approach,” said Teri Heiland, ITI VP of R&D.

Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI to use the Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ vaccine platform.

In the agreement, ITI receives an option for an exclusive Worldwide license to the Biojector®-2000 that triggers based on the achievement of certain clinical milestones. The agreement contains provisions for development rights and exclusive license of Bioject’s ID Pen intradermal injection system for various fields of use.

"Bioject’s needle-free intradermal injection devices have a strong track record of clinical benefit with DNA vaccines” said Mark Logomasini, President and CEO of Bioject. “These benefits have been demonstrated in several programs at ITI. This agreement establishes a framework for bringing these programs and their associated products to market. We are very much looking forward to continued work with the team at ITI.”

Bioject's advanced needle-free technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. The diameter of the orifice is smaller than the diameter of a human hair. This creates an ultra-fine stream of medicine able to penetrate skin without use of a needle. Bioject's technology is available for use with a wide range of injectable drugs and has the ability to deliver medicine at a range of depths and injection volumes.

ITI is a rapidly growing biotechnology company pioneering breakthrough vaccines. Its LAMP-vax has been described as the missing link in enhancing the effectiveness of DNA vaccines. LAMP immunotherapy formulations have been safely applied and immunogenic for patients with prostate cancer, acute myeloid leukemia and melanoma.

ITI has made great progress over the past few years and has emerged with a new class of DNA-based allergy immunotherapeutic vaccines poised to transform the worldwide allergy market. The company believes Bioject’s novel delivery technologies hold promise to deliver LAMP-vax vaccines to the right populations of cells in the right part of the body and further strengthen the application of ITI core technology, first in allergies and in other immunotherapeutic areas.

“The right delivery is key to a well-designed vaccine approach,” said Teri Heiland, ITI VP of R&D. “In our hands, we have shown that LAMP-vax delivered with Bioject has the potential to enhance the right kind of immune response to our vaccines while providing a safe delivery method. I am excited about the potential of this collaboration to further support acceleration of our product development.”

About Bioject Medical Technologies, Inc.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle- free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations. http://www.bioject.com

About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-Vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit http://www.immunomix.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sia Anagnostou

Melissa Kemp
@immunomix
Follow >
Immunomic Therapeutics, Inc
since: 09/2012
Like >
Immunomic Therapeutics, Inc.

Visit website